Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ...

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

However, the company's financial results have been pretty strong. And if DexCom can keep that up in its next quarterly update ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging reliance on A1c for diabetes management.

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst ...

Dexcom shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.mo ...

DexCom was named a Barron’s stock pick in July. After DexCom shifted its focus to the Type 2 population last year, Type 1 ...